IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 199 filers reported holding IMPAX LABORATORIES INC in Q3 2016. The put-call ratio across all filers is 1,411.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $5,000 | -16.7% | 272 | 0.0% | 0.00% | – |
| Q3 2017 | $6,000 | +50.0% | 272 | 0.0% | 0.00% | – |
| Q2 2017 | $4,000 | -99.7% | 272 | -99.8% | 0.00% | -100.0% |
| Q1 2017 | $1,497,000 | -4.5% | 118,327 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $1,568,000 | -61.6% | 118,327 | -31.3% | 0.01% | -59.4% |
| Q3 2016 | $4,082,000 | -16.7% | 172,237 | +1.3% | 0.03% | -23.8% |
| Q2 2016 | $4,901,000 | -10.0% | 170,057 | 0.0% | 0.04% | -19.2% |
| Q1 2016 | $5,445,000 | -28.3% | 170,057 | -4.2% | 0.05% | -28.8% |
| Q4 2015 | $7,589,000 | +17.6% | 177,473 | -3.2% | 0.07% | +7.4% |
| Q3 2015 | $6,452,000 | -23.7% | 183,256 | -0.5% | 0.07% | -34.6% |
| Q2 2015 | $8,461,000 | -2.0% | 184,265 | 0.0% | 0.10% | +6.1% |
| Q1 2015 | $8,636,000 | +35.4% | 184,265 | -8.4% | 0.10% | +34.2% |
| Q4 2014 | $6,376,000 | – | 201,240 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aravt Global | 2,670,000 | $125,143,000 | 9.40% |
| Krensavage Asset Management, LLC | 410,944 | $19,261,000 | 8.77% |
| BANBURY PARTNERS LLC | 292,660 | $13,717,000 | 8.70% |
| Slate Path Capital LP | 1,935,000 | $90,693,000 | 5.72% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 285,000 | $13,358,000 | 4.69% |
| Orbimed Advisors | 6,678,000 | $312,998,000 | 2.67% |
| Pennant Capital Management, LLC | 2,025,000 | $94,912,000 | 1.78% |
| Iguana Healthcare Management, LLC | 75,000 | $3,515,000 | 1.48% |
| Leonard Capital Management, Inc. | 89,235 | $4,182,000 | 1.44% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $11,718,000 | 1.23% |